ASCEND BY NTHRYS
Research Abroad Products

Immunotechnology Project Topics

Browse all focused areas across all project categories under this field.

Showing 37–48 of 200 project topics
HER2-Directed Bispecific Antibody Therapeutic Asset
Clinical-stage or marketed bispecific antibody targeting HER2 and immune effector cells for solid tumor treatment. Generates revenue through product sales, milestone payments from partners, and potential licensing of technology to other indications.
Immunotechnology Bispecific Antibody Platforms Click to view more details →
Bispecific Antibody Stability and Manufacturability Prediction AI
Machine learning platform predicting protein stability, manufacturability, and off-target binding risk for novel bispecific antibody designs before synthesis. Monetizes as a B2B SaaS tool reducing R&D costs and accelerating clinical candidate selection.
Immunotechnology Bispecific Antibody Platforms Click to view more details →
Next-Generation Bispecific Antibody Format Discovery Service
Specialized discovery service offering access to proprietary bispecific antibody formats, screening campaigns, and hit identification using combinatorial libraries. Generates revenue through platform access fees, discovery phase payments, and royalties on development programs.
Immunotechnology Bispecific Antibody Platforms Click to view more details →
Bispecific Antibody Clinical Translation and Regulatory Consulting
Expert consulting service guiding companies through CMC, IND-enabling studies, and regulatory strategy for bispecific antibody programs. Monetizes through fixed-fee consulting engagements, milestone-based project services, and retainer relationships with biotech sponsors.
Immunotechnology Bispecific Antibody Platforms Click to view more details →
PD-L1 Expression Profiling SaaS Platform
A cloud-based diagnostic platform that quantifies PD-L1 expression levels in patient tumor samples using advanced imaging and computational algorithms. Enables oncologists to identify checkpoint inhibitor responders, reducing treatment failures and increasing patient stratification accuracy for precision medicine.
Checkpoint Inhibitor Technology Development Click to view more details →
Dual Checkpoint Inhibitor Combination Discovery Engine
An AI-powered drug discovery tool that screens and predicts synergistic combinations of PD-1, PD-L1, CTLA-4, and LAG-3 inhibitors for specific cancer types. Accelerates pharmaceutical R&D timelines and enables licensing partnerships worth tens of millions in upfront and milestone payments.
Checkpoint Inhibitor Technology Development Click to view more details →
Real-Time Immunotherapy Response Monitoring Dashboard
A clinician-facing software platform that tracks immune checkpoint biomarkers and clinical outcomes during anti-PD-1/PD-L1 treatment in real time. Generates actionable insights for treatment optimization and early intervention, creating recurring SaaS revenue through hospital and clinic subscriptions.
Checkpoint Inhibitor Technology Development Click to view more details →
Checkpoint Inhibitor Manufacturing Quality Control Suite
An automated analytical software and hardware system that ensures manufacturing consistency and potency of checkpoint inhibitor biologics through continuous process monitoring. Reduces production costs, minimizes batch failures, and generates recurring revenue through licensing to biotech manufacturers and CMOs.
Checkpoint Inhibitor Technology Development Click to view more details →
Resistance Mechanism Detection and Prediction Biomarker Kit
A commercially available diagnostic kit that identifies molecular signatures predicting checkpoint inhibitor resistance, including tumor microenvironment composition and immune cell infiltration patterns. Generates high-margin recurring revenue through per-test pricing while enabling pharmaceutical companies to enrich clinical trial populations.
Checkpoint Inhibitor Technology Development Click to view more details →
Checkpoint Inhibitor Adverse Event Prediction Artificial Intelligence
An enterprise AI platform that predicts severe immune-related adverse events before clinical manifestation using genomic, proteomic, and clinical data inputs. Enables pharmaceutical companies to improve safety monitoring in clinical trials and post-market surveillance, unlocking regulatory approval advantages and liability mitigation.
Checkpoint Inhibitor Technology Development Click to view more details →
Next-Generation Checkpoint Inhibitor Affinity Optimization Platform
A proprietary computational and wet-lab platform engineering checkpoint inhibitors with enhanced tumor selectivity and reduced off-target binding through structure-based design. Generates licensing fees and royalties from pharmaceutical partners seeking differentiated clinical candidates with superior safety profiles.
Checkpoint Inhibitor Technology Development Click to view more details →
Multi-Cancer Checkpoint Inhibitor Clinical Trial Matching Service
A digital health service platform connecting cancer patients to optimal checkpoint inhibitor trials based on their tumor genetics and immune profiles. Generates revenue through patient enrollment fees, trial sponsor contracts, and subscription-based provider dashboards for trial recruitment optimization.
Checkpoint Inhibitor Technology Development Click to view more details →